What happened
Basel-headquartered neurotech company Indivi has bought Cogitat, a spin-out from Imperial College London that builds deep learning systems to interpret cognitive function from EEG recordings, Tech.eu reported. Indivi, which also runs offices in Córdoba, Spain, and Boston, works with biopharmaceutical sponsors to help them run smaller early-stage trials and identify treatment effects with more certainty.
Cogitat's main asset is NeuroRVQ, an EEG foundation model behind brainwave decoders intended to function for any person and on any device. Cogitat CEO and founder Allan Ponniah said each brain differs, and that the model handles that variation without per-person training, spotting subtle shifts in activity that were hard to identify before. He framed this as a fix for the failure to catch early biological changes that indicate whether a treatment will work.
Indivi CEO and founder Guilhem Dupont said the brain remains among the hardest organs to understand and measure, and that the model surfaces signals closer to its underlying biology. He said the near-term aim is giving drug developers earlier evidence on treatments for brain conditions, with possible longer-term uses beyond life sciences. Indivi plans to keep building the model with Cogitat's team, starting with experimental Alzheimer's treatments.
Context
Before the deal, Indivi's multimodal platform relied on smartphone-based motor and cognitive tests, with work covering Parkinson's disease, multiple sclerosis, Alzheimer's and related dementias, and neuromuscular conditions such as FSHD. Cogitat has described its ambition as doing for brain signals what large language models did for text. EEG is seen as a more direct view of brain activity that may reveal changes before memory or thinking problems appear.
ブリーフィング
1週間のテックニュースを1通のメールで。
読む価値のある記事を毎週お届けします。配信停止はいつでも可能です。
